Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Coherus Oncology (CHRS) Enterprise Value (2016 - 2025)

Coherus Oncology's Enterprise Value history spans 13 years, with the latest figure at -$172.1 million for Q4 2025.

  • For Q4 2025, Enterprise Value fell 36.62% year-over-year to -$172.1 million; the TTM value through Dec 2025 reached -$172.1 million, down 36.62%, while the annual FY2025 figure was -$172.1 million, 36.62% down from the prior year.
  • Enterprise Value for Q4 2025 was -$172.1 million at Coherus Oncology, up from -$191.7 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$82.4 million in Q1 2025 and bottomed at -$468.7 million in Q3 2021.
  • The 5-year median for Enterprise Value is -$191.7 million (2022), against an average of -$233.4 million.
  • The largest annual shift saw Enterprise Value crashed 106.73% in 2021 before it soared 68.28% in 2025.
  • A 5-year view of Enterprise Value shows it stood at -$417.2 million in 2021, then soared by 54.05% to -$191.7 million in 2022, then surged by 38.57% to -$117.7 million in 2023, then fell by 7.0% to -$126.0 million in 2024, then crashed by 36.62% to -$172.1 million in 2025.
  • Per Business Quant, the three most recent readings for CHRS's Enterprise Value are -$172.1 million (Q4 2025), -$191.7 million (Q3 2025), and -$237.6 million (Q2 2025).